Aelis Farma SA (EPA: AELIS)

Market Cap	26.01M
Revenue (ttm)	10.78M
Net Income (ttm)	-7.03M
Shares Out	13.62M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754
Average Volume	1,117
Open	1.900
Previous Close	1.900
Day's Range	1.900 - 1.930
52-Week Range	1.900 - 13.600
Beta	0.30
RSI	34.89
Earnings Date	Apr 3, 2025

About Aelis Farma

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 26
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2023, Aelis Farma's revenue was 12.36 million, an increase of 47.75% compared to the previous year's 8.36 million. Losses were -5.08 million, -64.46% less than in 2022.